KR102474757B1 - 발현 강화 유전자좌의 사용에 기초하여 항체를 만들기 위한 조성물 및 방법 - Google Patents

발현 강화 유전자좌의 사용에 기초하여 항체를 만들기 위한 조성물 및 방법 Download PDF

Info

Publication number
KR102474757B1
KR102474757B1 KR1020217035334A KR20217035334A KR102474757B1 KR 102474757 B1 KR102474757 B1 KR 102474757B1 KR 1020217035334 A KR1020217035334 A KR 1020217035334A KR 20217035334 A KR20217035334 A KR 20217035334A KR 102474757 B1 KR102474757 B1 KR 102474757B1
Authority
KR
South Korea
Prior art keywords
nucleic acid
nucleotide sequence
cell
exogenous nucleic
rrs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217035334A
Other languages
English (en)
Korean (ko)
Other versions
KR20210135340A (ko
Inventor
로버트 밥
다리야 부라코프
강 첸
제임스 피. 팬들
Original Assignee
리제너론 파마슈티칼스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 리제너론 파마슈티칼스 인코포레이티드 filed Critical 리제너론 파마슈티칼스 인코포레이티드
Publication of KR20210135340A publication Critical patent/KR20210135340A/ko
Application granted granted Critical
Publication of KR102474757B1 publication Critical patent/KR102474757B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/65—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Analytical Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
KR1020217035334A 2016-04-20 2017-04-20 발현 강화 유전자좌의 사용에 기초하여 항체를 만들기 위한 조성물 및 방법 Active KR102474757B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662325385P 2016-04-20 2016-04-20
US62/325,385 2016-04-20
KR1020187029371A KR20180134894A (ko) 2016-04-20 2017-04-20 발현 강화 유전자좌의 사용에 기초하여 항체를 만들기 위한 조성물 및 방법
PCT/US2017/028552 WO2017184831A1 (en) 2016-04-20 2017-04-20 Compositions and methods for making antibodies based on use of an expression-enhancing locus

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020187029371A Division KR20180134894A (ko) 2016-04-20 2017-04-20 발현 강화 유전자좌의 사용에 기초하여 항체를 만들기 위한 조성물 및 방법

Publications (2)

Publication Number Publication Date
KR20210135340A KR20210135340A (ko) 2021-11-12
KR102474757B1 true KR102474757B1 (ko) 2022-12-07

Family

ID=58701850

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020187029371A Ceased KR20180134894A (ko) 2016-04-20 2017-04-20 발현 강화 유전자좌의 사용에 기초하여 항체를 만들기 위한 조성물 및 방법
KR1020217035334A Active KR102474757B1 (ko) 2016-04-20 2017-04-20 발현 강화 유전자좌의 사용에 기초하여 항체를 만들기 위한 조성물 및 방법

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020187029371A Ceased KR20180134894A (ko) 2016-04-20 2017-04-20 발현 강화 유전자좌의 사용에 기초하여 항체를 만들기 위한 조성물 및 방법

Country Status (15)

Country Link
US (2) US11530277B2 (enExample)
EP (1) EP3445780A1 (enExample)
JP (3) JP7134868B2 (enExample)
KR (2) KR20180134894A (enExample)
CN (2) CN109071633B (enExample)
AR (1) AR108295A1 (enExample)
AU (2) AU2017253240B2 (enExample)
BR (1) BR112018071285A2 (enExample)
CA (1) CA3015371A1 (enExample)
EA (1) EA201892137A1 (enExample)
IL (2) IL309065A (enExample)
MX (2) MX2018012866A (enExample)
SG (2) SG10202010156XA (enExample)
TW (1) TW201803981A (enExample)
WO (1) WO2017184831A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3015371A1 (en) 2016-04-20 2017-10-26 Regeneron Pharmaceuticals, Inc. Compositions and methods for making antibodies based on use of an expression-enhancing locus
IL275462B1 (en) * 2017-12-22 2025-09-01 Genentech Inc Targeted integration of nucleic acids
WO2020034097A1 (en) * 2018-08-14 2020-02-20 Wuxi Biologics (Shanghai) Co., Ltd. Transcriptional regulatory element and its use in enhancing the expression of exogenous protein
EP3870604B1 (en) * 2018-10-26 2022-11-23 F. Hoffmann-La Roche AG Multispecific antibody screening method using recombinase mediated cassette exchange
CN113631711B (zh) * 2018-12-21 2025-03-04 豪夫迈·罗氏有限公司 核酸的靶向整合
AU2020253023B2 (en) 2019-03-29 2022-07-14 F. Hoffmann-La Roche Ag Method for the generation of an FcRn expressing cell by targeted integration of multiple expression cassettes in a defined organization
WO2020204055A1 (ja) 2019-04-02 2020-10-08 中外製薬株式会社 標的特異的な外来遺伝子の導入方法
MX2021015537A (es) * 2019-06-19 2022-02-10 Hoffmann La Roche Metodo para la generacion de una celula que expresa anticuerpo biespecifico multivalente mediante la integracion diana de casetes de expresion multiples en una organizacion definida.
MX2021015540A (es) * 2019-06-19 2022-02-10 Hoffmann La Roche Metodo para la generacion de una celula que expresa un anticuerpo trivalente mediante la integracion dirigida de multiples casetes de expresion en una organizacion definida.
AU2020294878A1 (en) * 2019-06-19 2021-12-23 F. Hoffmann-La Roche Ag Method for the generation of a multivalent, multispecific antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization
WO2020254357A1 (en) 2019-06-19 2020-12-24 F. Hoffmann-La Roche Ag Method for the generation of a protein expressing cell by targeted integration using cre mrna
CN114008081A (zh) * 2019-06-19 2022-02-01 豪夫迈·罗氏有限公司 通过以限定的组织形式靶向整合多个表达盒来产生二价双特异性抗体表达细胞的方法
CN114080454A (zh) * 2019-06-26 2022-02-22 豪夫迈·罗氏有限公司 核酸的随机化构型靶向整合
WO2021140180A2 (en) * 2020-01-10 2021-07-15 F. Hoffmann-La Roche Ag Method for the assembly of large nucleic acids from short fragments
KR20240117146A (ko) * 2021-12-22 2024-07-31 제넨테크, 인크. 다중 벡터 재조합효소 매개 카세트 교환
WO2025054526A1 (en) 2023-09-07 2025-03-13 Regeneron Pharmaceuticals, Inc. Production and purification of covalently surface modified adeno-associated virus
CN119955730A (zh) * 2023-11-08 2025-05-09 深圳太力生物技术有限责任公司 一种细胞株及其制备方法与应用
WO2025111473A1 (en) 2023-11-21 2025-05-30 Regeneron Pharmaceuticals, Inc. Covalently surface modified adeno-associated virus production by in vitro conjugation, and purification of covalently surface modified adeno-associated virus

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008151219A1 (en) * 2007-06-04 2008-12-11 Regeneron Pharmaceuticals, Inc. Enhanced expression and stability regions
WO2013190032A1 (en) 2012-06-22 2013-12-27 Lonza Biologics Plc Site-specific integration
WO2014121087A1 (en) * 2013-02-01 2014-08-07 Regeneron Pharmaceuticals, Inc. Antibodies comprising chimeric constant domains

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US6800457B2 (en) 1998-09-22 2004-10-05 Bristol-Myers Squibb Company Expression vectors containing hot spot for increased recombinant protein expression in transfected cells
ATE340856T1 (de) 2000-08-07 2006-10-15 Serono Genetics Inst Sa Mit schizophrenie zusammenhängendes gen und protein
GB0209884D0 (en) 2002-04-30 2002-06-05 Ares Trading Sa Proteins
DK1531666T3 (da) 2002-05-29 2014-01-13 Regeneron Pharma Inducerbart eukaryot-ekspressionssystem
JP2006512061A (ja) 2002-11-14 2006-04-13 ジェネンテック・インコーポレーテッド イントロン融合コンストラクトおよび高発現産生細胞系を選択するための使用方法
DK3050963T3 (da) 2005-03-31 2019-12-09 Chugai Pharmaceutical Co Ltd Fremgangsmåde til fremstilling af polypeptid ved regulering af arrangement
EP1999154B1 (en) 2006-03-24 2012-10-24 Merck Patent GmbH Engineered heterodimeric protein domains
NZ573557A (en) 2006-06-02 2010-08-27 Regeneron Pharma High affinity antibodies to human il-6 receptor
JP2010514416A (ja) 2006-12-21 2010-05-06 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 新規な方法
WO2008089396A1 (en) 2007-01-19 2008-07-24 Invitrogen Corporation Compositions and methods for genetic manipulation and monitoring of cell lines
CA2681974C (en) 2007-03-29 2019-12-31 Genmab A/S Bispecific antibodies and methods for production thereof
WO2009089004A1 (en) 2008-01-07 2009-07-16 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
ES2661074T3 (es) 2009-06-02 2018-03-27 Regeneron Pharmaceuticals, Inc. Células deficientes de fucosilación
SI2975051T1 (sl) 2009-06-26 2021-08-31 Regeneron Pharmaceuticals, Inc. Zlahka izolirana bispecifična protitelesa z nativnim imunoglobulinskim formatom
AU2010296018B2 (en) 2009-09-16 2016-05-05 Genentech, Inc. Coiled coil and/or tether containing protein complexes and uses thereof
PL2560993T3 (pl) 2010-04-20 2024-11-04 Genmab A/S Heterodimeryczne białka zawierające region FC przeciwciała i sposoby ich wytwarzania
PL2606064T3 (pl) 2010-08-16 2015-07-31 Novimmune Sa Sposoby wytwarzania wieloswoistych i wielowartościowych przeciwciał
MY172718A (en) 2011-08-05 2019-12-11 Regeneron Pharma Humanized universal light chain mice
TWI641687B (zh) 2012-05-29 2018-11-21 美商再生元醫藥公司 生產細胞株增強子
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
TWI745610B (zh) 2012-11-14 2021-11-11 美商再生元醫藥公司 重組細胞表面捕捉蛋白質
US20140308285A1 (en) 2013-03-15 2014-10-16 Amgen Inc. Heterodimeric bispecific antibodies
TWI728373B (zh) 2013-12-23 2021-05-21 美商建南德克公司 抗體及使用方法
TWI701042B (zh) 2014-03-19 2020-08-11 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
AU2015335921B2 (en) * 2014-10-23 2020-06-25 Regeneron Pharmaceuticals, Inc. Novel CHO integration sites and uses thereof
AU2016325630B2 (en) 2015-09-23 2022-11-17 Regeneron Pharmaceuticals, Inc. Optimized anti-CD3 bispecific antibodies and uses thereof
CA3015371A1 (en) 2016-04-20 2017-10-26 Regeneron Pharmaceuticals, Inc. Compositions and methods for making antibodies based on use of an expression-enhancing locus

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008151219A1 (en) * 2007-06-04 2008-12-11 Regeneron Pharmaceuticals, Inc. Enhanced expression and stability regions
WO2013190032A1 (en) 2012-06-22 2013-12-27 Lonza Biologics Plc Site-specific integration
WO2014121087A1 (en) * 2013-02-01 2014-08-07 Regeneron Pharmaceuticals, Inc. Antibodies comprising chimeric constant domains

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Biotechnol Prog.,31(6):1645-1556(2015.)
Cytotechnology.,51(3):171-182(2006.7.)

Also Published As

Publication number Publication date
MX2018012866A (es) 2019-03-11
JP7134868B2 (ja) 2022-09-12
KR20210135340A (ko) 2021-11-12
AU2017253240A1 (en) 2018-09-20
KR20180134894A (ko) 2018-12-19
JP7789143B2 (ja) 2025-12-19
JP2024164196A (ja) 2024-11-26
US12503520B2 (en) 2025-12-23
EP3445780A1 (en) 2019-02-27
AU2024220126A1 (en) 2024-10-17
TW201803981A (zh) 2018-02-01
SG11201807881VA (en) 2018-10-30
SG10202010156XA (en) 2020-11-27
BR112018071285A2 (pt) 2019-02-12
CA3015371A1 (en) 2017-10-26
IL309065A (en) 2024-02-01
US20230322956A1 (en) 2023-10-12
AR108295A1 (es) 2018-08-08
EA201892137A1 (ru) 2019-03-29
AU2017253240B2 (en) 2024-07-04
JP2019514358A (ja) 2019-06-06
US20190263937A1 (en) 2019-08-29
IL262268B1 (en) 2024-01-01
WO2017184831A1 (en) 2017-10-26
CN116004544A (zh) 2023-04-25
JP2022164824A (ja) 2022-10-27
MX2024014381A (es) 2024-12-06
CN109071633B (zh) 2022-11-18
JP7546015B2 (ja) 2024-09-05
US11530277B2 (en) 2022-12-20
IL262268B2 (en) 2024-05-01
IL262268A (en) 2018-11-29
CN109071633A (zh) 2018-12-21

Similar Documents

Publication Publication Date Title
US12503520B2 (en) Compositions and methods for making antibodies based on use of an expression-enhancing locus
US20230130799A1 (en) Compositions and methods for making antibodies based on use of expression-enhancing loci
KR102906454B1 (ko) 발현 강화 유전자좌의 사용에 기초하여 항체를 만들기 위한 조성물 및 방법
EA044725B1 (ru) Композиции и способы получения антител, основанные на применении локусов, обеспечивающих повышенную экспрессию
JP2025188169A (ja) 発現強化座位の使用に基づいた抗体を作製するための組成物および方法
EA046654B1 (ru) Композиции и способы получения антител, основанные на применении локусов, обеспечивающих повышенную экспрессию

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 4